EirGenix expects to receive FDA approval for its first product, EG12014, by the end of the year, and to achieve a market share of 8% after three years on the market, which will bring the company significant cash flow and regular profits after 2025. EirGenix is also aggressively expanding its production and will invest in phases in 2030 to move towards becoming a major CDMO in Asia.

The company has already signed a licensing agreement with Sandoz, the world's leading generic drug manufacturer, and is expected to achieve a market share of 8% at the end of this year. Based on the annual sales volume of the original manufacturer, it is estimated that the peak sales will generate significant cash flow and profit contribution in one year.

In addition to EG12014, EG1206A and EG12043, another Her2-related therapeutic product, have also entered the development stage, and the former is targeted to complete its first phase in the second quarter of 2023.

In addition to its own product line, EirGenix is also continuing to expand its production capacity. In addition to the 25,500 litres of production capacity it will have in the first phase, it is also planning to invest $8.5 billion in a component plant in the Qiaotou Park area of Southern Taiwan Science Park, and is expected to add another 50,000 litres of production capacity in 2026, 2028 and 2030.

In the opinion of the company, EirGenix will be able to rely on its milestone income this year and next year to challenge the challenge of not incurring a loss for the whole year, and will become a regular profit-making biotech company after 2024 when its own product sales take off.